GO:0090321 positive regulation of chylomicron remnant clearance: Lipid Clearance Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0090321 describes any biological process that increases the rate, frequency, or extent of chylomicron remnant clearance, the receptor-mediated removal of chylomicron remnants from blood into liver cells.
• Chylomicron remnants are triglyceride-depleted, cholesterol-enriched particles derived from intestinal chylomicrons after lipoprotein lipase-mediated lipolysis.
• The low-density lipoprotein receptor (LDLR) and related receptors mediate hepatic uptake of remnants, and LDLR expression levels directly influence remnant clearance rates in humans.
• Liver cell cooperation, including hepatocytes, Kupffer cells, and sinusoidal endothelial cells, is required for efficient remnant processing and degradation.
• Genetic and molecular studies link remnant clearance pathways to metabolic traits such as body mass index and to late-onset Alzheimer's disease risk.
• Experimental models for studying GO:0090321 include LDLR knockout and knock-in mice, human LDLR point-mutation cell lines, and CRISPR-engineered hepatic cell models.
Description
GO:0090321, positive regulation of chylomicron remnant clearance, is a biological process term that captures any mechanism increasing the rate, frequency, or extent of chylomicron remnant removal from the bloodstream. Chylomicron remnants are the triglyceride-depleted, cholesterol-rich particles that remain after chylomicrons undergo lipolysis by lipoprotein lipase in peripheral tissues. Their clearance occurs primarily in the liver via receptor-mediated endocytosis, followed by degradation of constituent parts. This process is critical for postprandial lipid homeostasis and for preventing the accumulation of atherogenic remnant particles. Researchers study GO:0090321 because defects in remnant clearance contribute to dyslipidemia, cardiovascular risk, and metabolic disease. The low-density lipoprotein receptor (LDLR) is a central mediator of hepatic remnant uptake, and its expression level correlates with remnant clearance efficiency in human subjects. Beyond LDLR, liver cell cooperation involving hepatocytes, Kupffer cells, and sinusoidal endothelial cells supports efficient remnant processing. Advances in transcriptomic and genetic approaches, including weighted gene co-expression network analysis of monozygotic twins, have identified modules and hub genes related to body mass index that intersect with lipid clearance pathways. Additionally, shared genetic risk factors between sleep traits and late-onset Alzheimer's disease implicate lipid metabolism and immune pathways in neurodegeneration. Understanding positive regulation of chylomicron remnant clearance therefore bridges basic lipoprotein biology, metabolic genetics, and disease modeling.
positive regulation of chylomicron remnant clearance At A Glance
| GO ID | GO:0090321 |
|---|---|
| GO term | positive regulation of chylomicron remnant clearance |
| Ontology | biological_process |
| Synonym | none |
| Major function | Increases the rate, frequency, or extent of chylomicron remnant removal from blood via receptor-mediated endocytosis into liver cells and degradation of constituent parts |
| Related process | Chylomicron remnant clearance (GO:0034382 parent process) |
| Key receptor | LDLR mediates hepatic uptake of remnant particles |
| Key tissue | Liver, involving cooperation of hepatocytes, Kupffer cells, and sinusoidal endothelial cells |
| Physiological context | Postprandial lipid metabolism and lipoprotein remnant homeostasis |
What Is GO:0090321?
GO:0090321 is defined by QuickGO as any process that increases the rate, frequency, or extent of chylomicron remnant clearance. Chylomicron clearance is the process in which a chylomicron remnant is removed from the blood via receptor-mediated endocytosis into liver cells and its constituent parts degraded. In practical terms, this GO term covers molecular events, cellular activities, and regulatory signals that enhance the efficiency of remnant particle uptake and breakdown by the liver.
Why Is positive regulation of chylomicron remnant clearance Important in Cell Biology?
Positive regulation of chylomicron remnant clearance is essential for postprandial lipid homeostasis because it determines how quickly atherogenic remnant particles are removed from circulation. Impaired clearance leads to remnant accumulation, which is associated with dyslipidemia and increased cardiovascular risk. The liver's coordinated cellular architecture, including hepatocytes, Kupffer cells, and sinusoidal endothelial cells, is required for efficient remnant processing. Genetic studies of metabolic traits such as body mass index have identified co-expression modules and hub genes that overlap with lipid clearance pathways. Furthermore, shared genetic risk factors between sleep traits and late-onset Alzheimer's disease highlight lipid and immune mechanisms that may intersect with remnant clearance biology. Understanding this process therefore has implications for metabolic disease, neurodegeneration, and therapeutic target discovery.
• Regulates postprandial clearance of atherogenic chylomicron remnants, reducing cardiovascular risk.
• LDLR expression levels directly influence remnant clearance rates in humans.
• Liver cell cooperation, including hepatocytes, Kupffer cells, and sinusoidal endothelial cells, is required for efficient remnant processing.
• Dysregulation of remnant clearance contributes to dyslipidemia and metabolic disease.
• Genetic co-expression modules related to body mass index overlap with lipid metabolism pathways.
• Shared genetic risk factors between sleep and late-onset Alzheimer's disease implicate lipid and immune pathways.
• Provides a mechanistic framework for developing therapies targeting remnant cholesterol.
• Enables CRISPR-based modeling of LDLR variants and other genes affecting remnant uptake.
• Supports research into liver-specific gene regulation and receptor-mediated endocytosis.
• Connects basic lipoprotein biology to clinical outcomes in cardiovascular and neurodegenerative disease.
What Happens During positive regulation of chylomicron remnant clearance?
Formation and remodeling of chylomicron remnants
In simple terms: Chylomicrons lose their fat cargo and become smaller remnant particles.
Dietary fats and cholesterol are packaged into chylomicrons by the intestine. Lipoprotein lipase in peripheral tissues hydrolyzes core triglycerides, producing triglyceride-depleted, cholesterol-enriched chylomicron remnants. These remnants retain apolipoprotein E and apolipoprotein B-48, which are recognized by hepatic receptors. The remodeling step is a prerequisite for efficient clearance because remnant particles must reach a size and composition compatible with receptor-mediated uptake.
Hepatic receptor-mediated recognition and endocytosis
In simple terms: Liver receptors grab remnant particles and pull them inside liver cells.
The low-density lipoprotein receptor (LDLR) and related receptors on hepatocytes bind chylomicron remnants via apolipoprotein E and mediate their endocytosis. Studies in human subjects with varying LDLR expression demonstrate that receptor availability directly affects remnant clearance rates. Positive regulation of this step can occur through increased receptor expression, enhanced receptor recycling, or improved ligand affinity. Liver sinusoidal endothelial cells and Kupffer cells also participate in remnant processing, forming a coordinated cellular network.
Intracellular degradation of remnant constituents
In simple terms: Once inside, the remnant particle is broken down and its parts are recycled or excreted.
After endocytosis, chylomicron remnants are delivered to lysosomes where constituent lipids and proteins are degraded. Cholesterol and other lipids are then either stored, secreted into bile, or repackaged into lipoproteins for redistribution. Hepatocyte metabolic status influences the efficiency of this degradation phase. Cooperation among liver cell types ensures that remnants are fully processed and that toxic lipid intermediates do not accumulate.
Regulatory signals that enhance clearance
In simple terms: Hormones, nutrients, and gene expression changes can speed up the whole clearance process.
Positive regulation of chylomicron remnant clearance can be achieved through transcriptional upregulation of LDLR and related receptors, post-transcriptional stabilization of receptor mRNA, or signaling pathways that enhance endocytic flux. Metabolic states such as fasting and feeding alter hepatic receptor expression and lipoprotein processing capacity. Genetic variation in lipid metabolism genes, identified through co-expression network analysis, may also modulate clearance efficiency. These regulatory layers provide multiple entry points for experimental intervention.
Key Genes Involved in GO:0090321 positive regulation of chylomicron remnant clearance
The following genes and proteins are central to the positive regulation of chylomicron remnant clearance, based on published literature on lipoprotein metabolism and hepatic uptake.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LDLR | Mediates hepatic receptor-mediated endocytosis of chylomicron remnants | Central target for studying remnant clearance efficiency and dyslipidemia |
| APOE | Ligand on remnant particles recognized by hepatic receptors | Isoform-specific effects on remnant uptake and Alzheimer's disease risk |
| APOB | Structural apolipoprotein of chylomicrons and remnants | B-48 and B-100 variants affect particle metabolism |
| LPL | Hydrolyzes chylomicron triglycerides to generate remnants | Rate-limiting enzyme for remnant formation |
| LMF1 | Lipase maturation factor required for LPL activity | Modulates remnant generation capacity |
| APOC2 | Cofactor for lipoprotein lipase activity | Defects cause hypertriglyceridemia and impaired remnant formation |
| APOC3 | Inhibits lipoprotein lipase and hepatic remnant uptake | Therapeutic target for lowering remnant cholesterol |
| LIPC | Hepatic lipase involved in remnant remodeling | Affects remnant lipid composition and clearance |
| LRP1 | Receptor that contributes to hepatic remnant uptake | Cooperates with LDLR in liver clearance |
| SCARB1 | Scavenger receptor involved in lipoprotein uptake | Modulates hepatic lipid handling |
| CETP | Transfers lipids between lipoproteins, affecting remnant composition | Influences remnant cholesterol levels |
| ABCA1 | Mediates cholesterol efflux and HDL formation | Indirectly affects remnant metabolism |
| ABCG5 | Promotes biliary cholesterol excretion | Links remnant degradation to sterol output |
| ABCG8 | Heterodimerizes with ABCG5 for cholesterol excretion | Affects hepatic sterol balance |
| NR1H2 | Nuclear receptor regulating lipid metabolism genes | Transcriptional control of clearance pathways |
| NR1H3 | Nuclear receptor controlling cholesterol and fatty acid metabolism | Modulates hepatic lipid handling |
| SREBF2 | Master transcription factor for cholesterol homeostasis | Regulates LDLR expression and remnant uptake |
How Is positive regulation of chylomicron remnant clearance Regulated?
Positive regulation of chylomicron remnant clearance is controlled at multiple levels. Transcriptional regulation of LDLR and related receptors by sterol-responsive transcription factors such as SREBF2 adjusts hepatic uptake capacity according to cellular cholesterol status. Post-transcriptional mechanisms, including mRNA stability and receptor recycling, further tune clearance efficiency. Liver cell cooperation, involving hepatocytes, Kupffer cells, and sinusoidal endothelial cells, provides a tissue-level regulatory network that ensures efficient remnant processing. Genetic variation in lipid metabolism genes, as revealed by co-expression network analysis of metabolic traits, may also influence clearance capacity. Additionally, shared genetic pathways between sleep traits and late-onset Alzheimer's disease suggest that systemic and neurological factors can intersect with lipid clearance regulation.
positive regulation of chylomicron remnant clearance and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LDLR | Dyslipidemia and cardiovascular disease | LDLR knockout hepatocyte cell line; LDLR knock-in mouse |
| APOE | Late-onset Alzheimer's disease and remnant clearance defects | APOE isoform-specific knock-in mice; APOE point-mutation cell lines |
| APOB | Familial hypobetalipoproteinemia and remnant metabolism disorders | APOB knockout HepG2 cells; APOB truncation knock-in models |
| APOC3 | Hypertriglyceridemia and remnant cholesterol elevation | APOC3 overexpression and knockout mouse models |
| LPL | Lipoprotein lipase deficiency and chylomicronemia | LPL knockout cell lines; LPL point-mutation knock-in mice |
Dyslipidemia and cardiovascular disease
Impaired chylomicron remnant clearance leads to accumulation of atherogenic remnant particles in circulation, a condition associated with dyslipidemia and increased cardiovascular risk. LDLR expression levels directly correlate with remnant clearance efficiency in human subjects, and reduced receptor availability exacerbates remnant retention. Therapeutic strategies aimed at enhancing positive regulation of remnant clearance therefore have potential for cardiovascular risk reduction.
Metabolic syndrome and obesity-related traits
Weighted gene co-expression network analysis of monozygotic twins has identified specific modules and hub genes related to body mass index that overlap with lipid metabolism pathways. These findings suggest that genetic networks controlling lipid clearance contribute to obesity-related metabolic phenotypes. Positive regulation of chylomicron remnant clearance may therefore be relevant to metabolic syndrome research.
Neurodegeneration and late-onset Alzheimer's disease
Shared genetic risk factors between sleep traits and late-onset Alzheimer's disease implicate lipid metabolism and immune pathways in neurodegeneration. Apolipoprotein E, a key ligand for remnant clearance, is a well-established Alzheimer's disease risk gene. These connections suggest that pathways regulating chylomicron remnant clearance may intersect with neurodegenerative disease mechanisms, warranting further investigation.
Liver disease and hepatic lipid handling
The liver is the primary site of chylomicron remnant clearance, and cooperation among hepatocytes, Kupffer cells, and sinusoidal endothelial cells is required for efficient processing. Disruption of this coordinated cellular network can impair remnant degradation and contribute to hepatic lipid accumulation. Studying positive regulation of remnant clearance in liver models may therefore inform understanding of hepatic steatosis and related conditions.
From positive regulation of chylomicron remnant clearance-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of LDLR impair chylomicron remnant clearance? | LDLR knockout hepatocyte cell line or LDLR knockout mouse |
| Does a specific LDLR point mutation alter receptor-mediated remnant uptake? | LDLR point-mutation knock-in cell model |
| Can overexpression of a candidate gene enhance remnant clearance? | Lentiviral or CRISPR-mediated overexpression in HepG2 or primary hepatocytes |
| Does a tagged receptor variant traffic normally to the cell surface? | Tagged knock-in of LDLR or LRP1 in hepatic cells |
| Which genes regulate remnant clearance in a genome-wide manner? | CRISPR library screening in hepatocyte cell lines |
| Does APOE isoform identity affect remnant uptake efficiency? | APOE isoform-specific knock-in mice or cell lines |
How to Study the positive regulation of chylomicron remnant clearance Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcriptome changes in lipid metabolism genes | Identifying co-expression modules related to body mass index and lipid clearance |
| CRISPR knockout screening | Loss-of-function effects on remnant uptake | Genome-wide discovery of positive regulators of clearance |
| CRISPR knock-in | Effects of specific point mutations on receptor function | Modeling LDLR or APOE variants associated with dyslipidemia |
| Lipoprotein kinetic study | In vivo remnant clearance rates | Assessing impact of LDLR expression levels in human subjects |
| Fluorescence microscopy | Cellular uptake and trafficking of labeled remnants | Visualizing receptor-mediated endocytosis in hepatocytes |
| Subcellular fractionation | Distribution of remnant components across organelles | Tracking lysosomal degradation of remnant particles |
| Western blotting | Protein expression of LDLR and related receptors | Validating receptor upregulation after genetic perturbation |
| Co-immunoprecipitation | Protein-protein interactions in clearance complexes | Identifying novel binding partners of hepatic receptors |
Transcriptomic profiling of lipid clearance pathways
RNA-seq and weighted gene co-expression network analysis can identify modules and hub genes associated with lipid metabolism and body mass index. These approaches reveal candidate regulators of chylomicron remnant clearance and prioritize genes for functional validation. Differential expression analysis between fasting and fed states can further highlight transcriptional programs controlling hepatic uptake capacity.
CRISPR-based functional genomics
CRISPR knockout and knock-in screens enable systematic interrogation of genes predicted to regulate remnant clearance. Pooled library screening in hepatocyte cell lines can identify positive and negative regulators of receptor-mediated endocytosis. Follow-up validation using individual gene knockouts or point mutations confirms causal roles.
Lipoprotein kinetic studies in model organisms
In vivo studies using intestinal fat infusion and lipoprotein fractionation measure remnant clearance rates in subjects with varying receptor expression. Mouse models with altered LDLR or apolipoprotein genes provide mechanistic insight into positive regulation of clearance. These methods directly quantify the physiological impact of genetic perturbations.
Imaging and biochemical assays of endocytosis
Fluorescently labeled remnant particles or receptor-specific ligands can be used to visualize uptake in cultured hepatocytes. Subcellular fractionation and co-localization studies track endocytic trafficking to lysosomes. Biochemical assays of cholesterol and triglyceride content in remnant fractions complement imaging approaches.
How CRISPR Can Be Used to Study GO:0090321 positive regulation of chylomicron remnant clearance
Knockout
CRISPR knockout of LDLR or other candidate genes in hepatocyte cell lines abolishes receptor-mediated remnant uptake, providing a clean loss-of-function model to test necessity. Knockout models can also be used in pooled screens to identify genes whose loss enhances or impairs clearance. These experiments establish causal links between specific genes and positive regulation of chylomicron remnant clearance.
Point Mutation
CRISPR-mediated point mutations can recreate naturally occurring variants in LDLR, APOE, or APOB that affect remnant binding or endocytosis. Such models are valuable for dissecting structure-function relationships and for testing whether specific amino acid changes alter clearance efficiency. Point-mutation cell lines complement knockout studies by revealing subtle functional defects.
Knock-in
Knock-in of tagged receptors or humanized apolipoprotein alleles allows tracking of receptor trafficking and remnant processing in a physiological context. Tagged knock-in models enable imaging of endocytic vesicles and lysosomal delivery. Humanized knock-in mice carrying human APOE or LDLR variants facilitate translational studies of remnant clearance.
Overexpression
CRISPR activation or lentiviral overexpression of LDLR and related receptors increases hepatic uptake capacity and enhances remnant clearance. Overexpression models are useful for testing whether a candidate gene is sufficient to accelerate clearance. These approaches can also be used to screen for genes that positively regulate the entire clearance pathway.
How EDITGENE Supports positive regulation of chylomicron remnant clearance Research
Researchers studying positive regulation of chylomicron remnant clearance-related genes often need to determine whether a candidate gene is causally involved in receptor-mediated uptake, remnant processing, or hepatic lipid handling. EDITGENE provides comprehensive CRISPR-based cell model services to support these investigations, from knockout validation to precise point-mutation modeling and genome-wide screening.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of chylomicron remnant clearance research.
Frequently Asked Questions About positive regulation of chylomicron remnant clearance
What is GO:0090321?
GO:0090321 is the Gene Ontology term for positive regulation of chylomicron remnant clearance, defined as any process that increases the rate, frequency, or extent of chylomicron remnant removal from blood via receptor-mediated endocytosis into liver cells and degradation of constituent parts.
What genes are involved in positive regulation of chylomicron remnant clearance?
Key genes include LDLR, APOE, APOB, LPL, APOC2, APOC3, LIPC, LRP1, and SCARB1, all of which participate in remnant formation, recognition, or hepatic uptake.
How does the LDLR mediate chylomicron remnant clearance?
LDLR on hepatocytes binds apolipoprotein E on remnant particles and mediates their endocytosis; human studies show that LDLR expression levels directly influence remnant clearance rates.
What happens when chylomicron remnant clearance is impaired?
Impaired clearance leads to accumulation of atherogenic remnant particles, which is associated with dyslipidemia and increased cardiovascular risk.
Which tissues are responsible for chylomicron remnant clearance?
The liver is the primary site, with cooperation among hepatocytes, Kupffer cells, and sinusoidal endothelial cells required for efficient remnant processing and degradation.
How can I study positive regulation of chylomicron remnant clearance in the lab?
Common approaches include CRISPR knockout of LDLR or related genes, lipoprotein kinetic studies in model organisms, RNA-seq, and fluorescence imaging of receptor-mediated endocytosis.
What is the role of APOE in chylomicron remnant clearance?
APOE on remnant particles serves as a ligand for hepatic receptors, and APOE isoforms differentially affect remnant uptake efficiency and Alzheimer's disease risk.
Are there mouse models for studying chylomicron remnant clearance?
Yes, LDLR knockout mice, APOE isoform-specific knock-in mice, and APOC3 transgenic models are widely used to study remnant clearance in vivo.
How does body mass index relate to chylomicron remnant clearance?
Weighted gene co-expression network analysis of monozygotic twins has identified modules and hub genes related to body mass index that overlap with lipid metabolism pathways.
What CRISPR services are available for studying chylomicron remnant clearance?
EDITGENE offers knockout, point-mutation, knock-in, tagged knock-in, overexpression cell models, and CRISPR library screening with bioinformatics support for genes involved in remnant clearance.
Conclusion
GO:0090321, positive regulation of chylomicron remnant clearance, represents a critical biological process at the intersection of lipoprotein metabolism, hepatic receptor biology, and metabolic disease. The process depends on coordinated action of receptors such as LDLR, apolipoproteins including APOE and APOB, and liver cell cooperation involving hepatocytes, Kupffer cells, and sinusoidal endothelial cells. Dysregulation of this pathway contributes to dyslipidemia, cardiovascular risk, and potentially neurodegenerative disease through shared genetic mechanisms. CRISPR-based cell models, including knockout, point-mutation, knock-in, and overexpression systems, provide powerful tools for dissecting the molecular players that positively regulate remnant clearance. Combined with transcriptomic and bioinformatic approaches, these models enable researchers to identify novel therapeutic targets and advance understanding of postprandial lipid homeostasis.
References
- 1. Kmieć Z. 2001. Cooperation of liver cells in health and disease.. Adv Anat Embryol Cell Biol 161:III-XIII, 1-151 PMID: 11729749
- 2. Chen D et al.. 2022. Sleep and Late-Onset Alzheimer's Disease: Shared Genetic Risk Factors, Drug Targets, Molecular Mechanisms, and Causal Effects.. Front Genet 13:794202 PMID: 35656316
- 3. Wang W et al.. 2017. Weighted gene co-expression network analysis of expression data of monozygotic twins identifies specific modules and hub genes related to BMI.. BMC Genomics 18(1):872 PMID: 29132311
- 4. Eriksson M et al.. 1991. Metabolism of lipoprotein remnants in humans. Studies during intestinal infusion of fat and cholesterol in subjects with varying expression of the low density lipoprotein receptor.. Arterioscler Thromb 11(4):827-37 PMID: 2065036
